1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,850 | 6,900 | 06.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | XFRA NEW INSTRUMENTS AVAILABLE ON 02.02.2026 | 253 | Xetra Newsboard | The following instruments on XETRA do have their first trading 02.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.02.2026
Aktien
1 CA00249P1053 AXA S.A. CDR
2 ARP125991090... ► Artikel lesen | |
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| 28.01. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-034 (GPRC5D/CD3 BISPECIFIC T-CELL ENGAGER, TCE) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA | 2 | HKEx | ||
| 22.01. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT ORPHAN DRUG DESIGNATION (ODD) OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) BY THE EUROPEAN ... | - | HKEx | ||
| 16.01. | Global News: Global Development Accelerates: Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Granted Fast Track Designation by FDA | 475 | Newsfile | Nanjing, China--(Newsfile Corp. - January 15, 2026) - Nanjing Leads Biolabs Co., Ltd. (HKE: 9887) ("Leads Biolabs" or the "Company") today announced that Opamtistomig (LBL-024), its core investigational... ► Artikel lesen | |
| 14.01. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT- LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA | 2 | HKEx | ||
| 31.12.25 | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 31.12.25 | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE OF THE BOARD OF DIRECTORS | 3 | HKEx | ||
| 31.12.25 | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 23.12.25 | Leads Biolabs and Dianthus dose first subject in LBL-047 trial | 2 | Investing.com | ||
| 23.12.25 | Dianthus Therapeutics, Inc.: Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) | 186 | GlobeNewswire (Europe) | LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress... ► Artikel lesen | |
| 23.12.25 | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-024 DOSED FIRST PATIENT IN PHASE IB/II TRIAL FOR PLATINUM-RESISTANT OVARIAN CANCER | 2 | HKEx | ||
| 23.12.25 | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-047 DOSED FIRST SUBJECT IN PHASE I TRIAL | 1 | HKEx | ||
| 17.12.25 | LEADS BIOLABS-B (09887): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 17.12.25 | LEADS BIOLABS-B (09887): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 17, 2025 | - | HKEx | ||
| 15.12.25 | LEADS BIOLABS-B (09887): INSIDE INFORMATION - PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION PROGRAM BY THE COMPANY | 1 | HKEx | ||
| 01.12.25 | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-047 RECEIVED IND APPROVAL FROM NMPA | 1 | HKEx | ||
| 28.11.25 | LEADS BIOLABS-B (09887): THE H SHARE AWARD SCHEME | - | HKEx | ||
| 28.11.25 | LEADS BIOLABS-B (09887): PROXY FORM FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON WEDNESDAY, DECEMBER 17, 2025 | 2 | HKEx | ||
| 28.11.25 | LEADS BIOLABS-B (09887): NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 28.11.25 | LEADS BIOLABS-B (09887): (1) PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME; (2) PROPOSED AUTHORIZATION TO THE BOARD OF DIRECTORS AND/OR THE DELEGATEE ... | - | HKEx |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Diagnostikkonzern Qiagen überrascht im Schlussquartal - Weiteres Wachstum 2026 | VENLO/HILDEN (dpa-AFX) - Qiagen hat 2025 von einer anziehenden Nachfrage nach seinen Kernprodukten profitiert. Dabei lief das Schlussquartal besser als vom Labordienstleister und Diagnostikkonzern... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| AGOMAB THERAPEUTICS | 14,650 | 0,00 % | AgomAb Therapeutics N.V.: Agomab Announces Pricing of Initial Public Offering | ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| SPYGLASS PHARMA | 26,400 | 0,00 % | SpyGlass Pharma Prices IPO At $16 Per Share | WASHINGTON (dpa-AFX) - SpyGlass Pharma, Inc. (SGP), a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9.38 million shares at $16 per share.The company... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,410 | +8,87 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen |
Das Unternehmen NANJING LEADS BIOLABS CO LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,450 Euro und damit -2,57 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANJING LEADS BIOLABS CO LTD finden Sie auf Wallstreet Online.